What the Wegovy pill actually is
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist: a medicine that mimics a natural gut hormone the body releases after eating. Until recently, the weight-management version — sold under the Wegovy brand — existed only as a once-weekly injection. The Wegovy pill is the same molecule reformulated as a once-daily tablet with a 25 mg maintenance dose, and Novo Nordisk describes it as the first oral GLP-1 receptor agonist licensed for weight management in adults.[1]
The Wegovy pill is oral semaglutide 25 mg — the same active ingredient as the injection, in a once-daily tablet. It is one option a prescriber may discuss for weight management, and it is prescription-only.
How the Wegovy pill works
As a GLP-1 receptor agonist, semaglutide acts on appetite-regulating areas of the brain: it increases fullness (satiety), reduces hunger and dampens food cravings, so most people eat less without consciously fighting their appetite.[2] Combined with a reduced-calorie diet and more activity, that drives the weight loss seen in the trials below.
The harder part is delivery. The tablet has to be taken to a strict routine: on an empty stomach with only a little water, and then a wait before eating, drinking anything else or taking other medicines.[2] Our dosage and how-to-take page sets out the tablet strengths and the daily routine in full.
Wegovy pill vs Wegovy injection — and vs Rybelsus
Three different semaglutide products are easy to confuse, so it helps to line them up. The Wegovy injection and the Wegovy pill are the same medicine in two forms, for the same purpose. Rybelsus is a separate, lower-dose oral semaglutide licensed for a different condition — type 2 diabetes, not weight management.
| Product | Form & frequency | Licensed use | Dose |
|---|---|---|---|
| Wegovy injection | Subcutaneous injection, once weekly | Weight management[6] | 2.4 mg once weekly (maintenance)[2] |
| Wegovy pill | Oral tablet, once daily | Weight management[1] | 25 mg once daily (maintenance)[1] |
| Rybelsus | Oral tablet, once daily | Type 2 diabetes[5] | 3, 7 or 14 mg once daily[5] |
Pill vs injection
The pill and the injection contain the same active ingredient, so the goal — appetite reduction leading to weight loss — is the same. What differs is the route and rhythm: a tablet swallowed once a day versus an injection under the skin once a week. The Pharmaceutical Journal reports that someone established on the 2.4 mg once-weekly injection can be moved directly onto the 25 mg once-daily tablet.[2] The two forms use different dose numbers, so their strengths cannot be compared like-for-like. Our pill vs injection comparison goes further.
Pill vs Rybelsus
This is the comparison people get wrong most often, because both are oral semaglutide made with the same absorption technology. The distinction is dose and purpose: Rybelsus is licensed for type 2 diabetes at 3, 7 or 14 mg once daily,[5] while the Wegovy pill is a higher-dose oral semaglutide — a 25 mg maintenance dose for weight management.[1] They are separate products with separate licences and dose ladders; one is not a substitute for the other, and a prescriber chooses which, if either, is appropriate.
Is the Wegovy pill licensed in the UK?
Yes — with important caveats about how you can actually get it. The Pharmaceutical Journal reports that the MHRA licensed oral semaglutide tablets for weight loss in June 2026 (reported as 11 June 2026), making the Wegovy pill an approved medicine in the UK.[2] But an MHRA licence is not NHS availability: the same report states the tablet was not on the NHS at approval, and that NHS funding would need a separate NICE technology appraisal — NICE being the body that decides which treatments the NHS pays for — with no confirmed date.[2] That mirrors injectable semaglutide, which was appraised and then offered only to defined groups of patients.[6]
The United States is a step ahead: the US Food and Drug Administration approved the oral semaglutide 25 mg tablet on 22 December 2025 for weight management, and also to reduce the risk of major adverse cardiovascular events in certain adults with overweight or obesity and established cardiovascular disease.[1][9] As of mid-2026 we found no confirmed European Union-wide approval, so status elsewhere should be checked against the relevant regulator.
| Country / region | Status |
|---|---|
| United States (FDA) | Approved 22 December 2025 for weight management[1] |
| United Kingdom (MHRA) | Licensed June 2026; not on the NHS at approval[2] — a UK pharmacy guide reports private-prescription availability[8] |
| European Union (EMA) | No EU-wide approval confirmed as of mid-2026 |
What the OASIS trial found
The tablet's weight-management evidence comes from the OASIS programme of phase 3 trials. The study behind the approved 25 mg dose was OASIS 4, which ran for 64 weeks in adults with obesity, or overweight with weight-related complications, without type 2 diabetes, comparing the tablet against placebo alongside lifestyle support.[3]
Novo Nordisk reports two headline figures, because trials measure effect in two ways. Among people who kept taking the tablet as intended, mean weight loss was about 16.6%, versus roughly 2.7% on placebo; measured across everyone regardless of how consistently they took it, it was about 13.6%, versus roughly 2.4% on placebo.[9] Around 76% of people on the tablet lost at least 5% of their body weight, against about 31% on placebo, and roughly one in three reached a 20% loss on the fuller-adherence measure — a figure nearer 30% when averaged across everyone.[9][3]
An earlier trial, OASIS 1, tested a higher 50 mg dose — not the strength that was licensed — and reported mean weight loss of 15.1% versus 2.4% on placebo at 68 weeks, published in The Lancet in 2023.[4] The on-label story, though, is OASIS 4 at 25 mg, published in the New England Journal of Medicine in September 2025.[3]
The 16.6% and 13.6% numbers are not a contradiction. One estimates the effect if a person keeps taking the medicine as intended; the other averages in everyone, including those who stopped or took it irregularly.
Side effects and safety
Like the injection, the tablet's most common side effects are gastrointestinal. In OASIS 4, gastrointestinal adverse events affected about 74% of people on oral semaglutide against 42% on placebo, and were mostly mild to moderate; the share who stopped because of side effects was similar for drug and placebo (about 7% versus 6%).[3] Novo Nordisk lists the usual semaglutide effects — nausea, diarrhoea, vomiting, constipation, stomach pain, headache and tiredness among them — and says the overall safety profile is comparable to earlier studies.[9]
Semaglutide carries a boxed warning in the US about a risk of thyroid C-cell tumours, based on animal studies, and it should not be used by people with certain thyroid or endocrine conditions.[9] These are decisions for a prescriber who knows your history. If you take any weight-loss medicine and experience side effects, report them through the MHRA Yellow Card scheme[7] and speak to your GP or pharmacist. Our side effects page covers the warnings in full.
How you would access it in the UK
The Wegovy pill is prescription-only: a prescriber decides whether it is appropriate, and only a GPhC-registered pharmacy can dispense it against a valid prescription after a consultation. It was not on the NHS at approval,[2] and a UK pharmacy guide reports it was available privately from early July 2026.[8] A website selling semaglutide with no prescription or clinical assessment is not operating lawfully, and what it supplies may not be a genuine, regulated medicine. To read more first, see our frequently asked questions or the development story behind the tablet.
Frequently asked questions
What is the Wegovy pill?
It is a once-daily tablet form of semaglutide — a GLP-1 receptor agonist — taken for weight management at a 25 mg maintenance dose. It is the same active ingredient as the once-weekly injection, swallowed rather than injected, and it is prescription-only.[1]
Is the Wegovy pill the same as Rybelsus?
Is the Wegovy pill available on the NHS?
Not at approval. The Pharmaceutical Journal reports the MHRA licensed the tablet in June 2026, but it was not on the NHS then; NHS funding would depend on a separate NICE appraisal, with no confirmed date.[2]
How much weight did people lose in the trials?
In OASIS 4, Novo Nordisk reports mean weight loss of about 16.6% among people who took oral semaglutide 25 mg as intended, and 13.6% regardless of adherence, versus roughly 2–3% on placebo over 64 weeks.[9]
Can I buy the Wegovy pill without a prescription?
No. It is prescription-only. Lawful UK supply happens only through a GPhC-registered pharmacy against a valid prescription, after a consultation, and only a prescriber can decide whether it is appropriate. A website offering it with no prescription or consultation is not operating lawfully.
References
- Novo Nordisk. Wegovy pill (oral semaglutide 25 mg) — FDA approval announcement, including US indication, dosing and OASIS 4 results. novonordisk.com
- The Pharmaceutical Journal. "MHRA approves semaglutide oral tablets for weight loss" — UK licence, NHS status and NICE appraisal (secondary source).
- American College of Cardiology. OASIS 4 trial summary (oral semaglutide 25 mg; published in the New England Journal of Medicine, 17 September 2025) — design, adverse events and outcomes (secondary source).
- The Lancet. OASIS 1: oral semaglutide 50 mg for weight management, 2023. thelancet.com
- US Food and Drug Administration. Rybelsus (oral semaglutide) prescribing information — strengths, type 2 diabetes indication and administration rules. accessdata.fda.gov
- National Institute for Health and Care Excellence. TA875: semaglutide for managing overweight and obesity (injectable form; context for the pill's likely NHS route). nice.org.uk
- MHRA. Yellow Card scheme — report a suspected side effect. yellowcard.mhra.gov.uk
- Bolt Pharmacy. Wegovy pill UK guide — private-prescription availability in the UK at launch (secondary source; UK pharmacy guide).
- PR Newswire (Novo Nordisk news release). "FDA approves Novo Nordisk's Wegovy pill, the first and only oral GLP-1 for weight loss in adults" — the common side-effect list, the statement that the safety profile is comparable to earlier semaglutide studies, and the US boxed warning and thyroid contraindications. PR Newswire, December 2025.